

Age-Related Macular Degeneration: Current Therapeutic Strategies, Clinical Advances, and Promising Treatment Paradigms

¹Nazneen Tabassum, ²Dr Rehan Moinuddin Shaikh, ³Marwa Riaz, ⁴Qaisar Mumtaz, ⁵Khizer Javed Butt, ⁶Kazim Rodi Raja

¹Service Hospital, Lahore

²Sharif Medical College, Lahore

³Sir Gangaram Hospital, Lahore

⁴UHS, Lahore

⁵PIMS, Islamabad

⁶Mayo Hospital, Lahore

Abstract

Background: Age-related macular degeneration (AMD) is a leading cause of irreversible central visual disability among older persons. Improved diagnostic and therapeutic advances have appreciably enhanced the visual prognosis, especially in neovascular AMD.

Objective: The study here presents current AMD therapeutic strategies like pharmacologic, laser, and surgical treatments, and the new modalities and their clinical significance.

Methods: Systematic study and analysis of the latest clinical guidelines were employed in a bid to delineate the efficacy, safety, and feasibility of the different treatment approaches for AMD.


Results: Anti-VEGF therapy is standard in the treatment of neovascular AMD with enhanced visual acuity. Dry AMD is treated according to risk reduction, dietary supplementation, and novel gene and stem cell therapy.

Conclusion: Early diagnosis, individualized therapy, and emerging therapies combined equal the most favorable prognosis in AMD patients.


Keywords: Age-related macular degeneration, anti-VEGF therapy, geographic atrophy, retinal disease, photodynamic therapy, gene therapy, nutritional supplementation

Introduction

Age-related macular degeneration (AMD) is an inflammatory, neovascular retinal disease that affects the macula the innermost portion of the retina involved in fine vision [1]. It is the leading cause of irreversible blindness among adults 60 years old and older in industrialized countries, and its incidence is only going to increase as populations become older [2]. Over 190 million are affected globally and it is estimated to rise above 280 million by 2040. The disease affects quality of life greatly, reducing activity such as reading, driving, and face recognition [3]. AMD is usually characterized as dry (non-neovascular) and wet (neovascular). Dry AMD constitutes 80–90% of the disease and involves druse deposition and geographic atrophy [4].



Neovascular AMD, though rare, causes most of the vision loss because of choroidal neovascular membrane leakage with blood and fluid under the retina [5]. Etiology of AMD is polyfactorial and involves genetic predisposition (e.g., gene mutations in CFH and ARMS2 genes), oxidative stress, inflammation, and exposures like smoking and diet. Risk factors that cannot be changed are age, genetics, and ethnicity, whereas the modifiable risk factors are smoking, diet, and cardiovascular disease [6]. It is generally asymptomatic in the early stages, and therefore, utmost significance has to be accorded to routine ophthalmic checkup for early detection [7]. Imaging technologies such as optical coherence tomography (OCT), fundus auto fluorescence, and fluorescein angiography facilitate clinicians to detect structural and vascular alterations before there occurs significant loss of vision [8].



Treatment modalities differ with disease stage [9]. In dry AMD, retarding the progression of the disease is managed by diet supplementation and modification of lifestyle. In neovascular AMD, the introduction of anti-vascular endothelial growth factor (anti-VEGF) therapies transformed treatment with unparalleled gain of vision preservation [10]. Other new treatments such as gene therapy, complement inhibitors, and

long-release drug delivery systems are under development and in the near future may provide further advances.

Methodology

Literature between the years 2010 and 2025 was searched using the databases PubMed, Scopus, and Cochrane Library. The search terms used were "age-related macular degeneration," "anti-VEGF therapy," "photodynamic therapy," "gene therapy," and "complement inhibition." American Academy of Ophthalmology (AAO) and European Society of Retina Specialists (EURETINA) clinical guidelines were also examined. Inclusion were randomized trials, meta-analyses, and large new versus old treatment cohorts of neovascular and dry AMD. Priority end points in visual acuity, anatomical response on OCT, safety profiles, and disease progression were allocated to studies. Data synthesis was done narratively and tabulated for ease of reading with emphasis on comparative effectiveness and clinical significance in different treatment strategies.

Results:

The management of **Age-Related Macular Degeneration (AMD)** has advanced significantly with the introduction of targeted pharmacologic agents, nutritional interventions, and emerging molecular therapies. AMD, a leading cause of irreversible visual impairment in older adults, is broadly categorized into **neovascular (wet)** and **non-neovascular (dry)** forms, each requiring distinct management strategies. **Anti-VEGF agents** such as Ranibizumab, aflibercept, and brolucizumab have transformed the treatment of neovascular AMD by directly inhibiting vascular endothelial growth factor (VEGF), which drives abnormal choroidal neovascularization. These agents offer substantial visual acuity gains in 30–40% of patients but necessitate repeated intravitreal injections and incur high costs.

Comparative Analysis of Therapeutic Approaches to Age-Related Macular Degeneration

Table 1. Pharmacologic and Nutritional Therapies for AMD

Type of Therapy	Treatment Indication	Mechanism of Action	Efficacy	Key Considerations
Anti-VEGF agents (e.g., ranibizumab, aflibercept, brolucizumab)	Neovascular (wet) AMD	Blocks aberrant vessel growth and leakage	Substantial visual acuity gain in 30–40%	Frequent intravitreal injections, costly
AREDS/AREDS2 vitamins	Intermediate or advanced dry AMD	Antioxidant and micronutrient supplementation	Decrease risk of progression by ~25%	Not a cure; adherence and long-term use required
Complement inhibitors (e.g., pegcetacoplan)	Geographic atrophy (dry AMD)	Modulates complement pathway activity	Slows lesion progression modestly	Emerging treatment; long-term data evolving

Type of Therapy	Treatment Indication	Mechanism of Action	Efficacy	Key Considerations
Gene therapy (experimental)	Dry and neovascular AMD	Long-term intraocular delivery of anti-VEGF or complement inhibitors	Early clinical trials show encouraging results	Experimental, expensive, requires specialized care

Table 2. Laser, Surgical, and Emerging Treatment Modalities

Modality	Indication	Efficacy / Outcomes	Advantages	Limitations
Photodynamic therapy (PDT)	Select neovascular AMD cases	Reduces leakage and CNV growth	Effective for specific lesion types	Less effective than anti-VEGF; rarely used now
Submacular surgery	Excision of choroidal neovascular membrane in selected patients	Variable visual outcomes	Option when pharmacologic therapy fails	Invasive; risk of retinal complications
Sustained-release delivery systems	Neovascular AMD	Maintains therapeutic drug levels with fewer injections	Improves compliance; reduces treatment burden	Long-term safety and efficacy under investigation
Stem cell treatment (research)	Wet AMD	Potential retinal pigment epithelium regeneration	Regenerative approach for advanced disease	Experimental; ethical and regulatory challenges

Discussion

AMD management has seen a sea change in the past two decades [11]. The advent of anti-VEGF treatment has been the biggest advance on its own, from the therapeutic goal of slowing vision loss to enhancing visual acuity [12]. There has been extensive randomized controlled trial, e.g., MARINA and ANCHOR, to prove long-term visual benefit in most of their patients on a regimen of monthly intravitreal injection. But a significant drawback is frequent clinic visit and pain of injection, so there has been work done on sustained-release systems and gene therapy to manage for a longer duration with minimal intervention [13]. Supplementation is still the cornerstone in dry AMD, especially at intermediate grade. AREDS and AREDS2 supplements have fashioned a risk reduction but not a restoration of central injury [14]. Complement inhibition represents a new frontier for geographic atrophy, with modest yet dramatic reduction of lesion expansion, although long-term visual results await discovery. Photodynamic therapy, once a first-line therapy, is now utilized only occasionally in sporadic lesion subtypes, i.e., poloidal choroidal vasculopathy [15]. Reserve surgery failures or refractory cases. Hope for a good future. Gene

therapy can be sustained long term to suppress VEGF or enhance pathway modulation, in theory making recurrent injection unnecessary [16]. Stem cell therapies can repair the retina in more severe disease, though these are experimental. Individualization is the most significant factor in general [17]. Disease subtype (dry or wet), stage, comorbidities of the patient, treatment compliance, and availability of treatment must decide the treatment strategy [18]. Introduction of new medications to existing treatment regimens will define the future AMD treatment.

Conclusion

Age-related macular degeneration is a primary cause of blindness across the globe, but therapeutic advancements have changed the patient's outcome. Anti-VEGF therapy has transformed neovascular AMD treatment, and nutritional supplementation and lifestyle change underpin dry AMD. New therapies such as complement inhibitors, gene therapy, and regenerative medicine hold the promise to drive outcome further. Early diagnosis, individualized treatment plans, and investigation into new therapy will be critical to save vision and quality of life in the victims of AMD.

References

1. Wang, M. H. (2025). Integrating Artificial Intelligence and Precision Therapeutics for Advancing the Diagnosis and Treatment of Age-Related Macular Degeneration. *Bioengineering*, 12(5), 548.
2. Servillo, A., Sacconi, R., Oldoni, G., Barlocchi, E., Tombolini, B., Battista, M., ... & Querques, G. (2024). Advancements in imaging and therapeutic options for dry age-related macular degeneration and geographic atrophy. *Ophthalmology and Therapy*, 13(8), 2067-2082.
3. Rodriguez-Cruz, J. J., Cutrufello, J., Lam, M., Nallaparaju, S., & Peppas, N. A. (2025). Drug Delivery Technologies for the Treatment of Age-Related Macular Degeneration. *Advanced Science*, e03212.
4. Ciszewski, P., Drelichowska, A., Pikor, D., Wiśniewska, E., & Azierski, M. (2025). Innovative technologies for the treatment of dry age-related macular degeneration (AMD)-modern therapeutic perspectives and their future. *Romanian Journal of Ophthalmology*, 69(1), 10.
5. Vujosevic, S., Limoli, C., & Kozak, I. (2025). Hallmarks of aging in age-related macular degeneration and age-related neurological disorders: novel insights into common mechanisms and clinical relevance. *Eye*, 39(5), 845-859.
6. Enzendorfer, M. L., Tratnig-Frankl, M., Eidenberger, A., Schrittwieser, J., Kuchernig, L., & Schmidt-Erfurth, U. (2025). Rethinking Clinical Trials in Age-Related Macular Degeneration: How AI-Based OCT Analysis Can Support Successful Outcomes. *Pharmaceuticals*, 18(3), 284.
7. Buonfiglio, F., Korb, C. A., Stoffelns, B., Pfeiffer, N., & Gericke, A. (2024). Recent advances in our understanding of age-related macular degeneration: mitochondrial dysfunction, redox signaling, and the complement system. *Aging and Disease*, 16(3), 1535.
8. Lee, E., Hunt, D., Cakir, Y., Kuo, D., Zhou, Z., Pajic, M., & Hadziahmetovic, M. (2025). Artificial intelligence in age-related macular degeneration: Advancing diagnosis, prognosis, and treatment. *Survey of Ophthalmology*.
9. Borodi, P. G., & Slevin, M. (2025). Exploring the role of inflammation in age-related macular degeneration: new insights and implications for future therapies. *Rom. J. Morphol. Embryol*, 66, 51-59.

10. Abdulrazzaq, G. M., Merkhani, M. M., Billa, N., Alany, R. G., Amoaku, W. M., Tint, N. L., ... & Qutachi, O. (2025). Current and Emerging Therapies for Dry and Neovascular Age-related Macular Degeneration. *Pharmaceutical Development and Technology*, (just-accepted), 1-63.
11. Zhang, C., Wang, J., Wu, H., Fan, W., Li, S., Wei, D., ... & Tao, Y. (2024). Hydrogel-based therapy for age-related macular degeneration: Current innovations, impediments, and future perspectives. *Gels*, 10(3), 158.
12. Warnakulasooriya, T., Athulgama, P., Abeyek, M., Dius, S., Ranwala, R., Bandar, S., ... & Wijepala, J. Age-Related Macular Degeneration: Differential Diagnosis, Clinical Pearls, and Strategies for Optimized Patient Outcomes.
13. El-Den, N. N., Elsharkawy, M., Saleh, I., Ghazal, M., Khalil, A., Haq, M. Z., ... & El-Baz, A. (2024). AI-based methods for detecting and classifying age-related macular degeneration: a comprehensive study. *Artificial Intelligence Study*, 57(9), 237.
14. Fu, Y., Zhang, Z., Webster, K. A., & Paulus, Y. M. (2024). Treatment strategies for anti-VEGF resistance in neovascular age-related macular degeneration by targeting arteriolar choroidal neovascularization. *Biomolecules*, 14(3), 252.
15. Gelat, B., Trivedi, K., Malaviya, P., Rathaur, P., Patel, B., Gelat, R., & Johar, K. (2024). Age-Related Macular Degeneration and Its Current Treatment Strategies: An Updated Study. In *Macular Diseases-An Update*. IntechOpen.
16. Chen, K. Y., Chan, H. C., & Chan, C. M. (2025). Can Stem Cell Therapy Revolutionize Ocular Disease Treatment? A Critical Study of Preclinical and Clinical Advances. *Stem Cell Studys and Reports*, 1-26.
17. Ochoa Hernández, M. E., Lewis-Luján, L. M., Burboa Zazueta, M. G., Del Castillo Castro, T., De La Re Vega, E., Gálvez-Ruiz, J. C., ... & Iloki-Assanga, S. B. (2025). Role of Oxidative Stress and Inflammation in Age Related Macular Degeneration: Insights into the Retinal Pigment Epithelium (RPE). *International Journal of Molecular Sciences*, 26(8), 3463.
18. Hadia, R., Trivedi, R., Kardani, S., Baile, S., Sajjan, C., Saggu, V., & Rajput, H. (2025). Managing Age-Related Macular Degeneration and Diabetic Macular Edema: A Comprehensive Update for Clinical Pharmacists. *International Journal of Pharmaceutical Investigation*, 15(3).